Nestle sales & earnings
This article was originally published in The Tan Sheet
Executive Summary
Nestle's Nutrition sales grew 6.1% to 6 bil. Swiss Francs ($4.68 bil.) helped by an improvement in China, while total sales for 2006 were 98.5 bil. Swiss Francs ($79.8 bil.) up 8.1%. The Switzerland-based firm achieved strong gains in infant nutrition as a result of the international roll-out of infant formula product Nestle NAN HA, according to a sales and earnings report. "We are seeing the benefits of the group's transformation into a nutrition, health and wellness company, with stronger innovation and branding, as well as improved efficiency," Nestle Chairman and CEO Peter Brabeck-Letmathe says. Products enriched with Branded Active Benefits achieved organic growth of more than 20% in 2006 with sales close to 4 bil. Swiss Francs ($3.24 bil.), the company says. Nestle says beverages achieved 8% organic growth to 25.9 bil. Swiss Francs ($21 bil.)...
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.